1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

BACKGROUND: CF-301 (exebacase) is a novel, recombinantly produced, bacteriophage-derived lysin (cell wall hydrolase) which is the first lysin to enter Phase 2 (Ph2) in the United States and is being studied for the treatment of S. aureus bacteremia including endocarditis. We examined the activity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasiou, Diane, Jandourek, Alena, Traczewski, Maria, Cassino, Cara, Schuch, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253852/
http://dx.doi.org/10.1093/ofid/ofy210.1173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253852/
http://dx.doi.org/10.1093/ofid/ofy210.1173

Ejemplares similares